Fiche publication
Date publication
mars 2017
Journal
American journal of hematology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre
Tous les auteurs :
Huet S, Szafer-Glusman E, Tesson B, Xerri L, Fairbrother WJ, Mukhyala K, Bolen C, Punnoose E, Tonon L, Chassagne-Clément C, Feugier P, Viari A, Jardin F, Salles G, Sujobert P
Lien Pubmed
Résumé
BCL2 mutations have been suggested to confer an adverse prognosis to follicular lymphoma (FL) patients, but their prognostic value has not been assessed in patients treated with a rituximab-containing regimen. Here we evaluated the prognostic value of BCL2 mutations in a large prospective cohort of 252 patients with FL treated with immunochemotherapy in the PRIMA randomized trial. Using a DNA-targeted sequencing approach, we detected amino acid altering mutations in 135 patients (54%) and showed that these mutations were probably mediated by the over-activation of AICDA (activation-induced cytidine deaminase) in the context of the t(14;18) translocation. The BCL2 variants identified in PRIMA patients affected the BH1, BH2, and BH3 functional motifs at a lower frequency than the N-terminus and flexible loop domain, with mostly conservative aminoacid changes. With a median follow-up of 6.7 years, we did not observe any impact of BCL2 mutations either on overall survival or progression-free survival.
Mots clés
Antineoplastic Agents, therapeutic use, Female, Humans, Lymphoma, Follicular, drug therapy, Male, Mutation, Prognosis, Proto-Oncogene Proteins c-bcl-2, genetics, Rituximab, therapeutic use, Translocation, Genetic, Treatment Outcome
Référence
Am. J. Hematol.. 2017 Mar;:
